Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Low dose DFD07 once daily · 1 trial · 1 indication
The proportion of subjects with complete clearance (absence of clinically visible or palpable AK lesions in the treatment area) of AK lesions at the End of Study Visit at 16 weeks (12 weeks treatment and 4 weeks treatment-free follow-up)
| Arm | Type | Description |
|---|---|---|
| Low dose DFD07 once daily | EXPERIMENTAL | - |
| High dose DFD07 once daily | EXPERIMENTAL | - |
| High dose DFD07 twice daily | EXPERIMENTAL | - |
| Placebo twice daily | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Low dose DFD07 once daily | DRUG | Low dose DFD07 once daily |
| High dose DFD07 once daily | DRUG | High dose DFD07 once daily |
| High dose DFD07 twice daily | DRUG | High dose DFD07 twice daily |
| Placebo twice daily | DRUG | Placebo twice daily |
Inclusion: 1. Subject understands the study procedures, is willing to comply with the study procedures and required visits, and agrees to participate by giving written informed consent. Subjects with a legal guardian, must have the written informed consent of the legal guardian. 2. Subject (or lega...
Low dose DFD07 is a small molecule being developed by Dr. Reddy's Laboratories Ltd for the treatment of actinic keratosis (AK), a skin condition characterized by rough, scaly patches on the skin caused by sun damage. It is applied as a cream to affected areas of the face and/or scalp.
Low dose DFD07 is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker symbol RDY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational treatment for actinic keratosis.
Low dose DFD07 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug is being studied for the treatment of actinic keratosis.
Low dose DFD07 has been studied in one completed Phase 2 clinical trial, identified as NCT03116698. This randomized, double-blind, placebo-controlled study evaluated two concentrations of DFD-07 cream in 240 subjects with actinic keratosis of the face and/or scalp over a 12-week treatment period in the United States.
Yes, Low dose DFD07 is the same as DFD-07. The drug is referred to by both names in clinical trial documentation. The Phase 2 study NCT03116698 evaluated DFD-07 cream, which is the same investigational treatment being developed for actinic keratosis.